Molecular Imaging of the Lung - Phase 2 (R01)
Post Date
March 17th 2015
Application Due Date
June 15th 2015
Funding Opportunity Number
RFA-HL-16-001
CFDA Number(s)
93.838
Funding Instrument Type(s)
Grant
Funding Activity Categories
Number of Awards
5
Eligibility Categories
State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Funding
-
Estimated Total Funding:
$3500000
-
Award Range:
$None - $450000
Grant Description
This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to develop novel in vivo imaging technologies using molecular probes that target pathways or cells involved in the pathobiology of pulmonary diseases. The long-term goal of this program is to develop novel molecular imaging entities and approaches that facilitate early detection and diagnosis of lung disease, enable noninvasive monitoring of lung disease progression and prognosis, and accelerate progress of cell-specific drug delivery and therapies.The previous FOA (RFA-HL-12-036 - Phase 1) supported projects to develop and validate innovative novel imaging agents and approaches that included target selection, probe development and production, and initial characterization of the probe. Phase 2 of this initiative will support studies that advance translation of identified probes and associated imaging approaches from animal models into applicability for human lung diseases. Phase 2 studies must include work performed in vivo using appropriate animal models of lung diseaseand studies using human tissues and/or cells. Applications proposing Investigational New Drug (IND)-enabling studies of novel probes and imaging approaches are encouraged. Applicants are not required to have been funded in Phase 1 (RFA-HL-12-036) in order to submit applications for Phase 2.
Contact Information
-
Agency
Department of Health and Human Services
-
Office:
National Institutes of Health
-
Agency Contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV -
Agency Mailing Address:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
- Agency Email Address:
-
More Information:
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-16-001.html
Get A Free Grant Assistance Kit
To start your application for a free grant package go to: